The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation in BRCA1 or BRCA2
Open accessAbstract
Purpose: Women with breast cancer diagnosed early in life comprise a substantial portion of those tested for BRCA1/BRCA2 mutations; however, little information is available on the subsequent risks of contralateral breast cancer in mutation carriers. This study assessed the risk of subsequent contralateral breast cancer associated with carrying a BRCA1 or BRCA2 mutation. Patients and Methods: In this nested case-control study, patients with contralateral breast cancer diagnosed 1 year or more after a first primary breast cancer (n = 705) and controls with unilateral breast cancer (n = 1,398) were ascertained from an underlying population-based cohort of 52,536 women diagnosed with a first invasive breast cancer before age 55 years. Interviews and medical record reviews were used to collect risk factor and treatment histories. All women were tested for BRCA1/BRCA2 mutations. Relative (rate ratios) and absolute (5- and 10-year cumulative) risks of developing contralateral breast cancer following a first invasive breast cancer were computed. Results: Compared with noncarriers, BRCA1 and BRCA2 mutation carriers had 4.5-fold (95% CI, 2.8- to 7.1-fold) and 3.4-fold (95% CI, 2.0- to 5.8-fold) increased risks of contralateral breast cancer, respectively. The relative risk of contralateral breast cancer for BRCA1 mutation carriers increased as age of first diagnosis decreased. Age-specific cumulative risks are provided for clinical guidance. Conclusion: The risks of subsequent contralateral breast cancer are substantial for women who carry a BRCA1/BRCA2 mutation. These findings have important clinical relevance regarding the assessment of BRCA1/BRCA2 status in patients with breast cancer and the counseling and clinical management of patients found to carry a mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We observed that family history is a predictor of CBC risk in both noncarriers and mutation carriers, which is in line with previous literature.19,21”
From Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers (2016) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Self-citationThe risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing, J., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,399
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.
Peto, J., Collins, N., Barfoot, R., Seal, S., Warren, W., Rahman, N., Easton, D., Evans, C., Deacon, J., & Stratton, M. R. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.11.943 · Cited by 909
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B. P., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 678
Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I. A., Warner, E., Olopade, O. I., Eisen, A. F., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 620
Anglian Breast Cancer Study Group (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1407 · Cited by 602
Unusual case of Smith‐Lemli‐Opitz syndrome “type II”
Seller, M. J., Russell, J., & Tint, G. S. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320560305 · Cited by 584
New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000.
Curtis, R. E., Freedman, D. M., Ron, E., Ries, L. A. G., Hacker, D. G., Edwards, B. K., Tucker, M., & Fraumeni, J. F. (2006) · Cited by 527
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452
Malone, K. E., Daling, J. R., Doody, D. R., Hsu, L., Bernstein, L., Coates, R. J., Marchbanks, P. A., Simon, M. S., McDonald, J. A., Norman, S. A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0503 · Cited by 373
Self-citationPierce, L. J., Levin, A. M., Rebbeck, T. R., Ben-David, M. A., Friedman, E., Solin, L. J., Harris, E. E., Gaffney, D. K., Haffty, B. G., Dawson, L. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7888 · Cited by 340
Epidemiology of contralateral breast cancer.
Chen, Y., Thompson, W. D., Semenciw, R. M., & Mao, Y. (1999) · PubMed · Cited by 334
Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Graeser, M. K., Engel, C., Rhiem, K., Gadzicki, D., Bick, U., Kast, K., Froster, U. G., Schlehe, B., Bechtold, A., Arnold, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9430 · Cited by 314
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
BRCA-associated breast cancer in young women.
Robson, M. E., Gilewski, T., Haas, B. R., Levin, D. R., Borgen, P. I., Rajan, P., Hirschaut, Y., Pressman, P., Rosen, P. P., LESSER, M. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1642 · Cited by 303
Variation of Breast Cancer Risk Among BRCA1/2 Carriers
Begg, C. B., Haile, R. W., Borg, Å., Malone, K. E., CONCANNON, P. J., Thomas, D. C., Langholz, B. M., Bernstein, L., Olsen, J. H., Lynch, C. F., et al. (2008) · JAMA · doi:10.1001/jama.2007.55-a · Cited by 279
Self-citationBrekelmans, C. T. M., Tilanus-Linthorst, M. M. A., Seynaeve, C., vd Ouweland, A., Menke-Pluymers, M. B. E., Bartels, C. C. M., Kriege, M., van Geel, A. N., Burger, C. W., Eggermont, A. M. M., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.12.009 · Cited by 233
Familial invasive breast cancers: worse outcome related to BRCA1 mutations.
Stoppa-Lyonnet, D., Ansquer, Y., Dreyfus, H., Gautier, C., Gauthier-Villars, M., Bourstyn, E., Clough, K., Magdelénat, H., Pouillart, P., Vincent-Salomon, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4053 · Cited by 224
Survival in hereditary breast cancer associated with germline mutations of BRCA2.
Verhoog, L., Brekelmans, C., Seynaeve, C., Dahmen, G., van Geel, A. V., Bartels, C., Tilanus-Linthorst, M., Wagner, A., Devilee, P., Halley, D., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3396 · Cited by 197
Robson, M., Levin, D., Federici, M. G., Satagopan, J. M., Bogolminy, F., Heerdt, A., Borgen, P., Mccormick, B., Hudis, C., Norton, L., et al. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.24.2112 · Cited by 181
Bernstein, J. L., Thompson, W. D., RISCH, N. J., & Holford, T. R. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116565 · Cited by 160
Self-citationCounter-Matching: A Stratified Nested Case-Control Sampling Method
Langholz, B. M., & Borgan, Ø. (1995) · Biometrika · doi:10.1093/biomet/82.1.69 · Cited by 155
Eng, C., Brody, L. C., Wagner, T. M. U., Devilee, P., Vijg, J., Szabo, C., Tavtigian, S. V., Nathanson, K. L., Ostrander, E. A., & Frank, T. S. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.12.824 · Cited by 142
Survival and prognostic factors in BRCA1-associated breast cancer
Brekelmans, C. T. M., Seynaeve, C., Menke-Pluymers, M., Brüggenwirth, H. T., Tilanus‐Linthorst, M. M. A., Bartels, C. C. M., Kriege, M., van Geel, A. N., Crépin, C., Blom, J., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj095 · Cited by 136
Kirova, Y. M., Stoppa-Lyonnet, D., Savignoni, A., Sigal-Zafrani, B., Fabre, N., & Fourquet, A. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.037 · Cited by 129
Bernstein, J. L., Langholz, B. M., Haile, R. W., Bernstein, L., Thomas, D. C., Stovall, M. A., Malone, K. E., Lynch, C. F., Olsen, J. H., Anton‐Culver, H., et al. (2004) · Breast Cancer Research · doi:10.1186/bcr771 · Cited by 128
Self-citationRobson, M. E., Svahn, T. H., McCormick, B. L., Borgen, P. I., Hudis, C. A., Norton, L., & Offit, K. (2004) · Cancer · doi:10.1002/cncr.20728 · Cited by 126
Prevalence of BRCA1 Mutation Carriers among U.S. Non-Hispanic Whites
Whittemore, A. S., Gong, G. D., John, E. M., McGuire, V. M., Li, F. P., Ostrow, K. L., DiCioccio, R. A., Felberg, A., & West, D. W. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.2078.13.12 · Cited by 124
Foulkes, W. D., Wong, N., Brunet, J., Bégin, L. R., Zhang, J. C., Martinez, J. J., Rozen, F., Tonin, P. N., Narod, S. A., Karp, S. E., et al. (1997) · PubMed · Cited by 122
Goffin, J. R., Chappuis, P. O., Bégin, L. R., Wong, N., Brunet, J., Hamel, N., Paradis, A.-J., Boyd, J. A., & Foulkes, W. D. (2003) · Cancer · doi:10.1002/cncr.11080 · Cited by 109
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome
Foulkes, W. D., Chappuis, P. O., Wong, N., Brunet, J.-S., Vesprini, D., Rozen, F., Yuan, Z. Q., Pollak, M. N., Kuperstein, G., Narod, S. A., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008340723974 · Cited by 86
Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer
Anton‐Culver, H., Cohen, P., Gildea, M., & Ziogas, A. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00110-6 · Cited by 80
Self-citationSurvival and Recurrence After Breast Cancer in BRCA1/2 Mutation Carriers
El-Tamer, M., Russo, D., Troxel, A., Bernardino, L. P., Mazziotta, R., Estabrook, A., Ditkoff, B., Schnabel, F., & Mansukhani, M. (2004) · Annals of Surgical Oncology · doi:10.1245/aso.2004.05.018 · Cited by 76
Familial breast cancer: an investigation into the outcome of treatment for early stage disease
Eccles, D., Simmonds, P., Goddard, J., Coultas, M., Hodgson, S., Lalloo, F., Evans, G., & Haites, N. (2001) · Familial Cancer · doi:10.1023/a:1013867917101 · Cited by 53
Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients.
Verhoog, L. C., Berns, E., Brekelmans, C. T. M., Seynaeve, C., Meijers-Heijboer, E. J., & Klijn, J. G. M. (2000) · PubMed · Cited by 35
Research works printed but not linked: 3
- Chen Y, 1999, Cancer Epidemiol Biomarkers Prev, 8, 855
- Foulkes WD, 1997, Clin Cancer Res, 3, 2465
- Verhoog LC, 2000, J Clin Oncol, 18, 119S
Cited by
Sorted by citations
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., Evans, D. G., Izatt, L., Eeles, R. A., Adlard, J., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt095 · Cited by 951
Molecular Subtypes and Local-Regional Control of Breast Cancer
Fragomeni, S. M., Sciallis, A. P., & Jeruss, J. S. (2017) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.08.005 · Cited by 489
Assessing the risk of second malignancies after modern radiotherapy
Newhauser, W. D., & Durante, M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3069 · Cited by 377
Cragun, D. L., Weidner, A. E., Lewis, C. C., Bonner, D. E., Kim, J., Vadaparampil, S. T., & Pal, T. (2017) · Cancer · doi:10.1002/cncr.30621 · Cited by 292
The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer
Hartmann, L. C., & Lindor, N. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1503523 · Cited by 254
Metadata
- Authors
- Malone, K. E., Begg, C. B., Haile, R. W., Borg, A., Concannon, P., Tellhed, L., Xue, S., Teraoka, S., Bernstein, L., Capanu, M., Reiner, A. S., Riedel, E. R., Thomas, D. C., Mellemkjær, L., Lynch, C. F., Boice, J. D., Anton-Culver, H., & Bernstein, J. L.
- Affiliations
- University of Southern California (US)
- From the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Preventive Medicine, University of Southern California, Los Angeles; Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute, City of Hope, Duarte; Department of Epidemiology, University of California at Irvine, Irvine, CA; Department of Oncology, Lund...
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2010-05-10
- Volume
- 28
- Issue
- 14
- Pages
- 2404-2410
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC2881721
- OpenAlex
- W2107243201
- Cited by
- 191
- References
- 36
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 12 · 2023: 9 · 2022: 4 · 2021: 5 · 2020: 18 · 2019: 5 · 2018: 10 · 2017: 14 · 2016: 19 · 2015: 16 · 2014: 11 · 2013: 17 · 2012: 20
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- National Institute on Aging (R01AG014358)
- National Cancer Institute (R01CA097397, U01CA083178, R01CA131010, R01CA129639)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- contralateral breast cancer, BRCA1 mutation, BRCA2 mutation, hereditary breast cancer, second primary cancer risk, cumulative risk, age at first diagnosis, mutation carriers, genetic counseling, early-onset breast cancer
- MeSH terms
- Adult, Age Factors, Breast Neoplasms, Denmark, DNA Mutational Analysis, Female, Humans, Middle Aged, Mutation, Neoplasm Recurrence, Local, Population Surveillance, Risk Factors, Time Factors, United States, Logistic Models, Case-Control Studies, Treatment Outcome, SEER Program, Risk Assessment, BRCA1 Protein, Genetic Predisposition to Disease, BRCA2 Protein, Apoptosis Regulatory Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
